Phase III, randomized study of docetaxel ( T ) + capecitabine ( X ) ( TX ) followed by cyclophosphamide ( C ) + epirubicin ( E ) + X ( CEX ) vs. T followed by C + E + fluorouracil ( F ) ( CEF ) as adjuvant treatment for patients (pts) with early breast cancer ( BC ): An interim safety analysis
- Kellokumpu-Lehtinen, P. (Speaker)
Activity: Talk or presentation › Conference presentation